Characteristics of study population
| Characteristic . | KMT2A . | Intermediate . | Adverse . | P* . |
|---|---|---|---|---|
| Patients, n | 426 | 2384 | 969 | |
| Centers, n | 112 | 165 | 141 | |
| Patient characteristics | ||||
| Patient age at HCT, n (%) | <.001 | |||
| Median (min-max) | 46.4 (18.2-70) | 54.5 (18-70) | 55.3 (18.5-70) | |
| 18-29 | 72 (17) | 237 (10) | 90 (9) | |
| 30-39 | 70 (16) | 249 (10) | 97 (10) | |
| 40-49 | 108 (25) | 418 (18) | 155 (16) | |
| 50-59 | 118 (28) | 730 (31) | 328 (34) | |
| 60-69 | 58 (14) | 750 (31) | 299 (31) | |
| Sex, n (%) | <.001 | |||
| Male | 179 (42) | 1222 (51) | 532 (55) | |
| Female | 247 (58) | 1162 (49) | 437 (45) | |
| Karnofsky score, n (%) | .004 | |||
| <90 | 136 (32) | 773 (32) | 375 (39) | |
| ≥90 | 280 (66) | 1576 (66) | 577 (60) | |
| Missing | 10 (2) | 35 (1) | 17 (2) | |
| HCT-CI, n (%) | <.001 | |||
| 0 | 89 (21) | 659 (28) | 227 (23) | |
| 1-2 | 116 (27) | 679 (28) | 225 (23) | |
| 3+ | 182 (43) | 832 (35) | 418 (43) | |
| Missing | 39 (9) | 214 (9) | 99 (10) | |
| Recipient CMV serostatus, n (%) | .73 | |||
| Negative | 147 (35) | 840 (35) | 340 (35) | |
| Positive | 277 (65) | 1516 (64) | 620 (64) | |
| Missing | 2 (0) | 28 (1) | 9 (1) | |
| Disease characteristics | ||||
| Type of AML, n (%) | <.001 | |||
| tAML | 88 (21) | 106 (4) | 87 (9) | |
| Antecedent MDS | 27 (6) | 449 (19) | 221 (23) | |
| De novo disease | 311 (73) | 1829 (77) | 661 (68) | |
| KMT2A subtype, n (%) | ||||
| KMT2A t(9;11) | 112 (26) | |||
| KMT2A t(10;11) | 28 (7) | |||
| KMT2A t(6;11) | 41 (10) | |||
| KMT2A t(11;19) | 62 (15) | |||
| KMT2A other | 47 (11) | |||
| KMT2A undefined | 136 (32) | |||
| Prior disease, n (%) | <.001 | |||
| AML, not therapy related | 338 (79) | 2278 (96) | 882 (91) | |
| HD | 5 (1) | 8 (0) | 5 (1) | |
| NHL | 14 (3) | 11 (0) | 12 (1) | |
| Breast cancer | 48 (11) | 36 (2) | 27 (3) | |
| Solid tumor | 9 (2) | 20 (1) | 18 (2) | |
| Other | 11 (3) | 31 (1) | 25 (3) | |
| Missing | 1 (0) | 0 (0) | 0 (0) | |
| Therapy for previous disease, n (%) | <.001 | |||
| AML, not therapy related | 338 (79) | 2278 (96) | 882 (91) | |
| Chemotherapy | 43 (10) | 45 (2) | 39 (4) | |
| Chemotherapy+radiation | 40 (9) | 39 (2) | 32 (3) | |
| Radiation alone | 2 (0) | 4 (0) | 7 (1) | |
| Auto HCT | 0 (0) | 5 (0) | 2 (0) | |
| Other | 3 (1) | 13 (1) | 7 (1) | |
| Extramedullary disease at diagnosis, n (%) | .35 | |||
| No | 394 (92) | 2195 (92) | 909 (94) | |
| Yes | 23 (5) | 148 (6) | 43 (4) | |
| Missing | 9 (2) | 41 (2) | 17 (2) | |
| White blood count at diagnosis, AML (×109/L), n (%) | <.001 | |||
| Median (min-max) | 1.2 (0.1-432) | 8.9 (0-427.5) | 3.6 (0-450) | |
| ≤10 | 191 (45) | 1117 (47) | 646 (67) | |
| 10-100 | 153 (36) | 831 (35) | 212 (22) | |
| >100 | 41 (10) | 213 (9) | 31 (3) | |
| Missing | 41 (10) | 223 (9) | 80 (8) | |
| Time to achieve CR1 (wk), n (%) | <.001 | |||
| Median (min-max) | 5.6 (0.4-45.6) | 6 (0.1-51.4) | 7 (0.1-50.7) | |
| ≤4 | 103 (24) | 493 (21) | 157 (16) | |
| 4-8 | 199 (47) | 1067 (45) | 415 (43) | |
| >8 | 121 (28) | 769 (32) | 381 (39) | |
| Missing | 3 (1) | 55 (2) | 16 (2) | |
| Time from CR1 to HCT (mo), n (%) | .04 | |||
| Median (min-max) | 2.8 (0.3-16.8) | 2.8 (0-86.3) | 2.6 (0.2-20.4) | |
| <3 | 239 (56) | 1290 (54) | 576 (59) | |
| 3-6 | 146 (34) | 823 (35) | 305 (31) | |
| >6 | 38 (9) | 216 (9) | 72 (7) | |
| Missing | 3 (1) | 55 (2) | 16 (2) | |
| Number of courses of induction for CR1 cases, n (%) | <.001 | |||
| 1 | 312 (73) | 1636 (69) | 593 (61) | |
| 2 | 64 (15) | 451 (19) | 245 (25) | |
| 3 | 13 (3) | 66 (3) | 28 (3) | |
| 4 | 0 | 14 (1) | 6 (1) | |
| 5 | 0 | 2 (0) | 0 | |
| Missing | 37 (9) | 215 (9) | 97 (10) | |
| MRD at time of HCT, n (%) | <.001 | |||
| Negative | 296 (69) | 1289 (54) | 594 (61) | |
| Positive | 69 (16) | 632 (27) | 210 (22) | |
| Missing | 61 (14) | 463 (19) | 165 (17) | |
| Transplant characteristics | ||||
| Donor type, n (%) | <.001 | |||
| HLA-identical sibling | 107 (25) | 736 (31) | 245 (25) | |
| Haploidentical | 23 (5) | 136 (6) | 68 (7) | |
| Other related | 9 (2) | 90 (4) | 22 (2) | |
| Well-matched unrelated (8/8) | 173 (41) | 912 (38) | 377 (39) | |
| Partially matched unrelated (7/8) | 39 (9) | 192 (8) | 99 (10) | |
| Cord blood | 75 (18) | 318 (13) | 158 (16) | |
| Conditioning intensity, n (%) | <.001 | |||
| MA-TBI | 105 (25) | 450 (19) | 175 (18) | |
| MA-chemotherapy | 183 (43) | 922 (39) | 370 (38) | |
| RIC/NMA | 129 (30) | 986 (41) | 416 (43) | |
| Under review | 9 (2) | 26 (1) | 8 (1) | |
| GVHD prophylaxis, n (%) | .33 | |||
| Post tx-cy | 35 (8) | 144 (6) | 66 (7) | |
| Tac based | 295 (69) | 1682 (71) | 662 (68) | |
| CSA based | 89 (21) | 491 (21) | 219 (23) | |
| Other | 2 (0) | 32 (1) | 7 (1) | |
| Missing | 5 (1) | 35 (1) | 15 (2) | |
| ATG/alemtuzumab, n (%) | .62 | |||
| ATG alone | 90 (21) | 557 (23) | 227 (23) | |
| Alemtuzumab alone | 9 (2) | 46 (2) | 20 (2) | |
| No ATG or alemtuzumab | 326 (77) | 1773 (74) | 722 (75) | |
| Missing | 1 (0) | 8 (0) | 0 | |
| Graft type, n (%) | <.001 | |||
| Bone marrow | 80 (19) | 318 (13) | 120 (12) | |
| Peripheral blood | 271 (64) | 1748 (73) | 691 (71) | |
| Cord blood | 75 (18) | 318 (13) | 158 (16) | |
| Year of transplant, n (%) | .02 | |||
| 2007 | 39 (9) | 214 (9) | 99 (10) | |
| 2008 | 57 (13) | 266 (11) | 123 (13) | |
| 2009 | 56 (13) | 262 (11) | 121 (12) | |
| 2010 | 60 (14) | 226 (9) | 107 (11) | |
| 2011 | 16 (4) | 132 (6) | 50 (5) | |
| 2012 | 22 (5) | 115 (5) | 38 (4) | |
| 2013 | 42 (10) | 269 (11) | 86 (9) | |
| 2014 | 56 (13) | 316 (13) | 143 (15) | |
| 2015 | 38 (9) | 321 (13) | 119 (12) | |
| 2016 | 40 (9) | 263 (11) | 83 (9) | |
| Follow-up - median (min-max) | 49.24 (3.32-126.41) | 37.96 (1.84-122.63) | 48.09 (2.89-120.23) |
| Characteristic . | KMT2A . | Intermediate . | Adverse . | P* . |
|---|---|---|---|---|
| Patients, n | 426 | 2384 | 969 | |
| Centers, n | 112 | 165 | 141 | |
| Patient characteristics | ||||
| Patient age at HCT, n (%) | <.001 | |||
| Median (min-max) | 46.4 (18.2-70) | 54.5 (18-70) | 55.3 (18.5-70) | |
| 18-29 | 72 (17) | 237 (10) | 90 (9) | |
| 30-39 | 70 (16) | 249 (10) | 97 (10) | |
| 40-49 | 108 (25) | 418 (18) | 155 (16) | |
| 50-59 | 118 (28) | 730 (31) | 328 (34) | |
| 60-69 | 58 (14) | 750 (31) | 299 (31) | |
| Sex, n (%) | <.001 | |||
| Male | 179 (42) | 1222 (51) | 532 (55) | |
| Female | 247 (58) | 1162 (49) | 437 (45) | |
| Karnofsky score, n (%) | .004 | |||
| <90 | 136 (32) | 773 (32) | 375 (39) | |
| ≥90 | 280 (66) | 1576 (66) | 577 (60) | |
| Missing | 10 (2) | 35 (1) | 17 (2) | |
| HCT-CI, n (%) | <.001 | |||
| 0 | 89 (21) | 659 (28) | 227 (23) | |
| 1-2 | 116 (27) | 679 (28) | 225 (23) | |
| 3+ | 182 (43) | 832 (35) | 418 (43) | |
| Missing | 39 (9) | 214 (9) | 99 (10) | |
| Recipient CMV serostatus, n (%) | .73 | |||
| Negative | 147 (35) | 840 (35) | 340 (35) | |
| Positive | 277 (65) | 1516 (64) | 620 (64) | |
| Missing | 2 (0) | 28 (1) | 9 (1) | |
| Disease characteristics | ||||
| Type of AML, n (%) | <.001 | |||
| tAML | 88 (21) | 106 (4) | 87 (9) | |
| Antecedent MDS | 27 (6) | 449 (19) | 221 (23) | |
| De novo disease | 311 (73) | 1829 (77) | 661 (68) | |
| KMT2A subtype, n (%) | ||||
| KMT2A t(9;11) | 112 (26) | |||
| KMT2A t(10;11) | 28 (7) | |||
| KMT2A t(6;11) | 41 (10) | |||
| KMT2A t(11;19) | 62 (15) | |||
| KMT2A other | 47 (11) | |||
| KMT2A undefined | 136 (32) | |||
| Prior disease, n (%) | <.001 | |||
| AML, not therapy related | 338 (79) | 2278 (96) | 882 (91) | |
| HD | 5 (1) | 8 (0) | 5 (1) | |
| NHL | 14 (3) | 11 (0) | 12 (1) | |
| Breast cancer | 48 (11) | 36 (2) | 27 (3) | |
| Solid tumor | 9 (2) | 20 (1) | 18 (2) | |
| Other | 11 (3) | 31 (1) | 25 (3) | |
| Missing | 1 (0) | 0 (0) | 0 (0) | |
| Therapy for previous disease, n (%) | <.001 | |||
| AML, not therapy related | 338 (79) | 2278 (96) | 882 (91) | |
| Chemotherapy | 43 (10) | 45 (2) | 39 (4) | |
| Chemotherapy+radiation | 40 (9) | 39 (2) | 32 (3) | |
| Radiation alone | 2 (0) | 4 (0) | 7 (1) | |
| Auto HCT | 0 (0) | 5 (0) | 2 (0) | |
| Other | 3 (1) | 13 (1) | 7 (1) | |
| Extramedullary disease at diagnosis, n (%) | .35 | |||
| No | 394 (92) | 2195 (92) | 909 (94) | |
| Yes | 23 (5) | 148 (6) | 43 (4) | |
| Missing | 9 (2) | 41 (2) | 17 (2) | |
| White blood count at diagnosis, AML (×109/L), n (%) | <.001 | |||
| Median (min-max) | 1.2 (0.1-432) | 8.9 (0-427.5) | 3.6 (0-450) | |
| ≤10 | 191 (45) | 1117 (47) | 646 (67) | |
| 10-100 | 153 (36) | 831 (35) | 212 (22) | |
| >100 | 41 (10) | 213 (9) | 31 (3) | |
| Missing | 41 (10) | 223 (9) | 80 (8) | |
| Time to achieve CR1 (wk), n (%) | <.001 | |||
| Median (min-max) | 5.6 (0.4-45.6) | 6 (0.1-51.4) | 7 (0.1-50.7) | |
| ≤4 | 103 (24) | 493 (21) | 157 (16) | |
| 4-8 | 199 (47) | 1067 (45) | 415 (43) | |
| >8 | 121 (28) | 769 (32) | 381 (39) | |
| Missing | 3 (1) | 55 (2) | 16 (2) | |
| Time from CR1 to HCT (mo), n (%) | .04 | |||
| Median (min-max) | 2.8 (0.3-16.8) | 2.8 (0-86.3) | 2.6 (0.2-20.4) | |
| <3 | 239 (56) | 1290 (54) | 576 (59) | |
| 3-6 | 146 (34) | 823 (35) | 305 (31) | |
| >6 | 38 (9) | 216 (9) | 72 (7) | |
| Missing | 3 (1) | 55 (2) | 16 (2) | |
| Number of courses of induction for CR1 cases, n (%) | <.001 | |||
| 1 | 312 (73) | 1636 (69) | 593 (61) | |
| 2 | 64 (15) | 451 (19) | 245 (25) | |
| 3 | 13 (3) | 66 (3) | 28 (3) | |
| 4 | 0 | 14 (1) | 6 (1) | |
| 5 | 0 | 2 (0) | 0 | |
| Missing | 37 (9) | 215 (9) | 97 (10) | |
| MRD at time of HCT, n (%) | <.001 | |||
| Negative | 296 (69) | 1289 (54) | 594 (61) | |
| Positive | 69 (16) | 632 (27) | 210 (22) | |
| Missing | 61 (14) | 463 (19) | 165 (17) | |
| Transplant characteristics | ||||
| Donor type, n (%) | <.001 | |||
| HLA-identical sibling | 107 (25) | 736 (31) | 245 (25) | |
| Haploidentical | 23 (5) | 136 (6) | 68 (7) | |
| Other related | 9 (2) | 90 (4) | 22 (2) | |
| Well-matched unrelated (8/8) | 173 (41) | 912 (38) | 377 (39) | |
| Partially matched unrelated (7/8) | 39 (9) | 192 (8) | 99 (10) | |
| Cord blood | 75 (18) | 318 (13) | 158 (16) | |
| Conditioning intensity, n (%) | <.001 | |||
| MA-TBI | 105 (25) | 450 (19) | 175 (18) | |
| MA-chemotherapy | 183 (43) | 922 (39) | 370 (38) | |
| RIC/NMA | 129 (30) | 986 (41) | 416 (43) | |
| Under review | 9 (2) | 26 (1) | 8 (1) | |
| GVHD prophylaxis, n (%) | .33 | |||
| Post tx-cy | 35 (8) | 144 (6) | 66 (7) | |
| Tac based | 295 (69) | 1682 (71) | 662 (68) | |
| CSA based | 89 (21) | 491 (21) | 219 (23) | |
| Other | 2 (0) | 32 (1) | 7 (1) | |
| Missing | 5 (1) | 35 (1) | 15 (2) | |
| ATG/alemtuzumab, n (%) | .62 | |||
| ATG alone | 90 (21) | 557 (23) | 227 (23) | |
| Alemtuzumab alone | 9 (2) | 46 (2) | 20 (2) | |
| No ATG or alemtuzumab | 326 (77) | 1773 (74) | 722 (75) | |
| Missing | 1 (0) | 8 (0) | 0 | |
| Graft type, n (%) | <.001 | |||
| Bone marrow | 80 (19) | 318 (13) | 120 (12) | |
| Peripheral blood | 271 (64) | 1748 (73) | 691 (71) | |
| Cord blood | 75 (18) | 318 (13) | 158 (16) | |
| Year of transplant, n (%) | .02 | |||
| 2007 | 39 (9) | 214 (9) | 99 (10) | |
| 2008 | 57 (13) | 266 (11) | 123 (13) | |
| 2009 | 56 (13) | 262 (11) | 121 (12) | |
| 2010 | 60 (14) | 226 (9) | 107 (11) | |
| 2011 | 16 (4) | 132 (6) | 50 (5) | |
| 2012 | 22 (5) | 115 (5) | 38 (4) | |
| 2013 | 42 (10) | 269 (11) | 86 (9) | |
| 2014 | 56 (13) | 316 (13) | 143 (15) | |
| 2015 | 38 (9) | 321 (13) | 119 (12) | |
| 2016 | 40 (9) | 263 (11) | 83 (9) | |
| Follow-up - median (min-max) | 49.24 (3.32-126.41) | 37.96 (1.84-122.63) | 48.09 (2.89-120.23) |
ATG, antithymocyte globulin; CSA, cyclosporine; HD, Hodgkin disease; KMT2A, mixed lineage leukemia; NA, not available; NHL, non-Hodgkin lymphoma; Tac, tacrolimus; Post tx-cy, Post-transplant cyclophosphamide.
Hypothesis testing: Pearson χ2 test.